Carlos Buesa
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Phenotype and psychometric characterization of Phelan-McDermid syndrome patients: pioneering towards personalized medicine.
Journal: Frontiers in psychiatry
Published: October 15, 2024
REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders.
Journal: Psychiatry and clinical neurosciences
Published: September 17, 2024
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.
Journal: The Lancet. Haematology
Published: March 15, 2024
Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.
Journal: Pharmaceutics
Published: June 03, 2022
Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology.
Journal: ACS pharmacology & translational science
Published: September 22, 2021
First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat.
Journal: CNS drugs
Published: February 12, 2021
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 14, 2020
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
Journal: Cancer cell
Published: May 19, 2017
Advances in the development of histone lysine demethylase inhibitors.
Journal: Current opinion in pharmacology
Published: February 23, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026